請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/74847
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張鑫(Shin C. Chang) | |
dc.contributor.author | Tsu-I Chen | en |
dc.contributor.author | 陳子翊 | zh_TW |
dc.date.accessioned | 2021-06-17T09:08:45Z | - |
dc.date.available | 2022-03-13 | |
dc.date.copyright | 2020-03-13 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-10-30 | |
dc.identifier.citation | 1. Villarejos VM, Visoná KA, Eduarte CA, Provost PJ, Hilleman MR. 1975. Evidence for viral hepatitis other than type A or type B among persons in Costa Rica. N Engl J Med. 293:1350-2.
2. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. 1975. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med. 292:767-70. 3. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 224:359-62. 4. Axley P, Ahmed Z, Ravi S, Singal AK. 2018. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. J Clin Transl Hepatol. 6:79-84. 5. Nakano T, Lau GM, Lau GM, Sugiyama M, Mizokami M. 2012. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int. 32:339-45. 6. Shepard CW, Finelli L, Alter MJ. 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 5:558-67. 7. Wilkins T, Malcolm JK, Raina D, Schade RR. 2010. Hepatitis C: diagnosis and treatment. Am Fam Physician. 81:1351-7. 8. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. 2011. An overview of HCV molecular biology, replication and immune responses. Viral J. 8:161 9. Anzola M, Burgos JJ. 2003. Hepatocellular carcinoma: molecular interactions between hepatitis C virus and p53 in hepatocarcinogenesis. Expert Rev Mol Med. 5:1-16 10. Scheel TK, Rice CM. 2013. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med. 19:837-49. 11. Ivanyi-Nagy R1, Kanevsky I, Gabus C, Lavergne JP, Ficheux D, Penin F, Fossé P, Darlix JL. 2006. Analysis of hepatitis C virus RNA dimerization and core-RNA interactions. Nucleic Acids Res. 34:2618-33. 12. Lai MC, Sun HS, Wang SW, Tarn WY. 2016. DDX3 functions in antiviral innate immunity through translational control of PACT. FEBS J. 283:88-101. 13. Rogacki K, Kasprzak A, Stępiński A. 2015. Alterations of Wnt/β-catenin signaling pathway in hepatocellular carcinomas associated with hepatitis C virus. Pol J Pathol. 66:9-21. 14. Yasui K, Wakita T, Tsukiyama-Kohara K, Funahashi SI, Ichikawa M, Kajita T, Moradpour D, Wands JR, Kohara M. 1998. The native form and maturation process of hepatitis C virus core protein. J Virol. 72:6048-55. 15. Chang SC, Yen JH, Kang HY, Jang MH, Chang MF. 1994. Nuclear localization signals in the core protein of hepatitis C virus. Biochem Biophys Res Commun. 205:1284-90. 16. Suzuki R, Sakamoto S, Tsutsumi T, Rikimaru A, Tanaka K, Shimoike T, Moriishi K, Iwasaki T, Mizumoto K, Matsuura Y, Miyamura T, Suzuki T. 2005. Molecular determinants for subcellular localization of hepatitis C virus core protein. J Virol. 79:1271-81. 17. Kasprzak A, Adamek A. 2008. Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol Res. 38:1-26. 18. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL. 2003. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem. 278:41624-30. 19. Steinmann E, Penin F, Kallis S, Patel AH, Bartenschlager R, Pietschmann T. 2007. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog. 3:e103. 20. Reed KE, Grakoui A, Rice CM. 1995. Hepatitis C virus-encoded NS2-3 protease: cleavage-site mutagenesis and requirements for bimolecular cleavage. J Virol. 69:4127-36. 21. Yan Y, Li Y, Munshi S, Sardana V, Cole JL, Sardana M, Steinkuehler C, Tomei L, De Francesco R, Kuo LC, Chen Z. 1998. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci. 7:837-47. 22. Pang PS, Jankowsky E, Planet PJ, Pyle AM. 2002. The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding. EMBO J. 21:1168-76. 23. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. 2005. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A. 102:17717-22. 24. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M Jr, Lemon SM. 2005. Immune evasion by hepatitis C virus NS3/4A cleavages of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 102: 2992-7. 25. Egger D, Wölk B, Gosert R, Bianchi L, Blum HE, Moradpour D, Bienz K. 2002. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol.76:5974-84. 26. Evans MJ, Rice CM, Goff SP. 2004. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci U S A. 101:13038-43. 27. Arima N, Kao CY, Licht T, Padmanabhan R, Sasaguri Y, Padmanabhan R. 2001. Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A. J Biol Chem. 276:12675-84. 28. Baek KH, Park HY, Kang CM, Kim SJ, Jeong SJ, Hong EK, Park JW, Sung YC, Suzuki T, Kim CM, Lee CW. 2006. Overexpression of hepatitis C virus NS5A protein induces chromosome instability via mitotic cell cycle dysregulation. J Mol Biol. 359:22-34 29. Wu SC, Chang SC, Wu HY, Liao PJ, Chang MF. 2008. Hepatitis C virus NS5A protein down-regulates the expression of spindle gene Aspm through PKR-p38 signaling pathway. J Biol Chem. 283:29396-404. 30. Kuo YC, Chen IY, Chang SC, Wu SC, Hung TM, Lee PH, Shimotohno K, Chang MF. 2014. Hepatitis C virus NS5A protein enhances gluconeogenesis through upregulation of Akt-/JNK-PEPCK signalling pathways. Liver Int. 34:1358-68. 31. Jin Z, Leveque V, Ma H, Johnson KA, Klumpp K. 2012. Assembly, purification, and pre-steady-state kinetic analysis of active RNA-dependent RNA polymerase elongation complex. J Biol Chem. 287:10674-83. 32. Cheng JC, Chang MF, Chang SC. 1999. Specific interaction between the hepatitis C virus NS5B RNA polymerase and the 3' end of the viral RNA. J Virol. 73:7044-9. 33. Randal J. 1999. Hepatitis C vaccine hampered by viral complexity, many technical restraints. J Natl Cancer Inst. 91:906-8. 34. Flyak AI, Ruiz S, Colbert MD, Luong T, Crowe JE Jr, Bailey JR, Bjorkman PJ. 2018. HCV broadly neutralizing antibodies use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design. Cell Host Microbe. 24:703-16. 35. Agrawal B, Gupta N, Vedi S, Singh S, Li W5, Garg S, Li J, Kumar R. 2019. Heterologous immunity between adenoviruses and hepatitis C virus (HCV): recombinant adenovirus vaccine vectors containing antigens from unrelated pathogens induce cross-reactive immunity against HCV antigens. Cells. 8, E507. 36. Liang TJ, Ghany MG. 2013. Current and future therapies for hepatitis C virus infection. N Engl J Med. 368:1907-17 37. World Health Organization. Hepatitis C. WHO http://www.who.int/news-room/fact-sheeets/detail/hepatitis-c (2017). 38. AASLD/IDSA HCV Guidance Panel. 2015. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 62:932-54. 39. Anzola M. 2004. Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat. 11:383-93. 40. Shimizu YK, Feinstone SM, Kohara M, Purcell RH, Yoshikura H.1996. Hepatitis C virus: detection of intracellular virus particles by electron microscopy. Hepatology. 23:205-9. 41. Errington W, Wardell AD, McDonald S, Goldin RD, McGarvey MJ. 1999. Subcellular localisation of NS3 in HCV-infected hepatocytes. J Med Virol. 59:456-62. 42. Falcón V, Acosta-Rivero N, Chinea G, Gavilondo J, de la Rosa MC, Menéndez I, Dueñas-Carrera S, Viña A, García W, Gra B, Noa M, Reytor E, Barceló MT, Alvarez F, Morales-Grillo J. 2003. Ultrastructural evidences of HCV infection in hepatocytes of chronically HCV-infected patients. Biochem Biophys Res Commun. 305:1085-90. 43. Kaito M, Watanabe S, Tsukiyama-Kohara K, Yamaguchi K, Kobayashi Y, Konishi M, Yokoi M, Ishida S, Suzuki S, Kohara M. 1994. Hepatitis C virus particle detected by immunoelectron microscopic study. J Gen Virol. 75:1755-60. 44. Moradpor D, Englert C, Wakita T, Wands JR. 1996. Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology. 222:51-63. 45. Moradpour D, Wakita T, Wands JR, Blum HE. 1998. Tightly regulated expression of the entire hepatitis C virus structural region in continuous human cell lines. Biochem Biophys Res Commun. 246:920-4 46. Mottola G, Cardinali G, Ceccacci A, Trozzi C, Bartholomew L, Torrisi MR, Pedrazzini E, Bonatti S, Migliaccio G. 2002. Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. Virology. 293:31-43. 47. Nielsen SU, Bassendine MF, Burt AD, Bevitt DJ, Toms GL. 2004. Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver. J Gen Virol. 85:1497-507. 48. Sakamuro D, Furukawa T, Takegami T. 1995. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol. 69:3893-6. 49. Zemel R, Gerechet S, Greif H, Bachmatove L, Birk Y, Golan-Goldhirsh A, Kunin M, Berdichevsky Y, Benhar I, Tur-Kaspa R. 2001. Cell transformation induced by hepatitis C virus NS3 serine protease. J Viral Hepat. 8:96-102. 50. Kou YH, Chang MF, Wang YM, Hung TM, Chang SC.. 2007. Differential requirements of NS4A for internal NS3 cleavage and polyprotein processing of hepatitis C virus. J Virol. 81:7999-8008. 51. Brenndörfer ED, Karthe J, Frelin L, Cebula P, Erhardt A, Schulte am Esch J, Hengel H, Bartenschlager R, Sällberg M, Häussinger D, Bode JG. 2009. Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase. Hepatology 49:1810-20. 52. Lai CK, Jeng KS, Machida K, Cheng YS, Lai MM. 2008. Hepatitis C virus NS3/4A protein interacts with ATM, impairs DNA repair and enhances sensitivity to ionizing radiation. Virology 370:295-309. 53. Machida K, Cheng KT, Lai CK, Jeng KS, Sung VM, Lai MM. 2006. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J Virol 80:7199-207. 54. Machida K, McNamara G, Cheng KT, Huang J, Wang CH, Comai L, Ou JH, Lai MM. 2010. Hepatitis C virus inhibits DNA damage repair through reactive oxygen and nitrogen species and by interfering with the ATM-NBS1/Mre11/Rad50 DNA repair pathway in monocytes and hepatocytes. J Immunol 185:6985-98. 55. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. 2004. Cell death by mitotic catastrophe: a molecular definition. Oncogene. 23:2825-37. 56. Meek K, Dang V, Lees-Miller SP. 2008. DNA-PK: the means to justify the ends? Adv Immunol. 99:33-58. 57. Goodarzi AA, Yu Y, Riballo E, Douglas P, Walker SA, Ye R, Härer C, Marchetti C, Morrice N, Jeggo PA, Lees-Miller SP. 2006. DNA-PK autophosphorylation facilitates Artemis endonuclease activity. EMBO J. 25:3880-9. 58. Gu J, Li S, Zhang X, Wang LC, Niewolik D, Schwarz K, Legerski RJ, Zandi E, Lieber MR. 2010. DNA-PKcs regulates a single-stranded DNA endonuclease activity of Artemis. DNA Repair (Amst). 9:429-37. 59. Karmakar P, Piotrowski J, Brosh RM Jr, Sommers JA, Miller SP, Cheng WH, Snowden CM, Ramsden DA, Bohr VA. 2002. Werner protein is a target of DNA-dependent protein kinase in vivo and in vitro, and its catalytic activities are regulated by phosphorylation. J Biol Chem. 277:18291-302. 60. Ochi T, Blackford AN, Coates J, Jhujh S, Mehmood S, Tamura N, Travers J, Wu Q, Draviam VM, Robinson CV, Blundell TL, Jackson SP. 2015. DNA repair. PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair. Science. 347:185-8. 61. Brouwer I, Sitters G, Candelli A, Heerema SJ, Heller I, de Melo AJ, Zhang H, Normanno D, Modesti M, Peterman EJ, Wuite GJ. 2016. Sliding sleeves of XRCC4-XLF bridge DNA and connect fragments of broken DNA. Nature. 535:566-9. 62. Grawunder U, Wilm M, Wu X, Kulesza P, Wilson TE, Mann M, Lieber MR. 1997. Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells Nature. 388:492-5. 63. McVey M, Lee SE. 2008. MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. Trends Genet. 24:529-38. 64. Wyatt DW, Feng W, Conlin MP, Yousefzadeh MJ, Roberts SA, Mieczkowski P, Wood RD, Gupta GP, Ramsden DA. 2016. Essential roles for polymerase θ-mediated end joining in the repair of chromosome breaks. Mol Cell. 63:662-73. 65. Sfeir A, Symington LS. 2015. Microhomology-mediated end joining: a back-up survival mechanism or dedicated pathway? Trends Biochem Sci. 40:701-14. 66. Robert I, Dantzer F, Reina-San-Martin B. 2009. Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination. J Exp Med. 206:1047-56. 67. Makharashvili N, Tubbs AT, Yang SH, Wang H, Barton O, Zhou Y, Deshpande RA, Lee JH, Lobrich M, Sleckman BP, Wu X, Paull TT. 2014. Catalytic and noncatalytic roles of the CtIP endonuclease in double-strand break end resection. Mol Cell. 54:1022-33. 68. Anand R, Ranjha L, Cannavo E, Cejka P. 2016. Phosphorylated CtIP functions as a co-factor of the MRE11-RAD50-NBS1 endonuclease in DNA end resection. Mol Cell. 64:940-50. 69. Yousefzadeh MJ, Wyatt DW, Takata K1, Mu Y, Hensley SC, Tomida J, Bylund GO, Doublié S, Johansson E, Ramsden DA, McBride KM, Wood RD. 2014. Mechanism of suppression of chromosomal instability by DNA polymerase POLQ. PLoS Genet. 10:e1004654. 70. Sartori AA, Lukas C, Coates J, Mistrik M, Fu S, Bartek J, Baer R, Lukas J, Jackson SP. 2007. Human CtIP promotes DNA end resection. Nature. 450:509-14. 71. Takeda S, Nakamura K, Taniguchi Y, Paull TT. 2007. Ctp1/CtIP and the MRN complex collaborate in the initial steps of homologous recombination. Mol Cell. 28:351-2. 72. Gravel S, Chapman JR, Magill C, Jackson SP. 2008.DNA helicases Sgs1 and BLM promote DNA double-strand break resection. Genes Dev. 22:2767-72. 73. Nimonkar AV, Ozsoy AZ, Genschel J, Modrich P, Kowalczykowski SC. 2008. Human exonuclease 1 and BLM helicase interact to resect DNA and initiate DNA repair. Proc Natl Acad Sci U S A. 105:16906-11. 74. Wold MS. 1997. Replication protein A: a heterotrimeric, single-stranded DNA-binding protein required for eukaryotic DNA metabolism. Annu Rev Biochem. 66:61- 92. 75. Moynahan ME, Pierce AJ, Jasin M. 2001. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 7:263-72. 76. Wu L, Hickson ID. 2003. The Bloom's syndrome helicase suppresses crossing over during homologous recombination. Nature. 426:870-4. 77. West SC. 2003. Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol. 4:435-45. 78. Bernstein DA, Keck JL. 2003. Domain mapping of Escherichia coli RecQ defines the roles of conserved N- and C-terminal regions in the RecQ family. Nucleic Acids Res. 31:2778-85. 79. Bohr VA. 2008. Rising from the RecQ-age: the role of human RecQ helicases in genome maintenance. Trends Biochem Sci. 33:609-20. 80. Kusumoto R, Dawut L, Marchetti C, Wan Lee J, Vindigni A, Ramsden D, Bohr VA. 2008. Werner protein cooperates with the XRCC4-DNA ligase IV complex in end-processing. Biochemistry. 47:7548-56. 81. Gray MD, Shen JC, Kamath-Loeb AS, Blank A, Sopher BL, Martin GM, Oshima J, Loeb LA. 1997. The Werner syndrome protein is a DNA helicase. Nat Genet. 17:100-3. 82. Compton SA, Tolun G, Kamath-Loeb AS, Loeb LA, Griffith JD. 2008. The Werner syndrome protein binds replication fork and holliday junction DNAs as an oligomer. J Biol Chem. 283:24478-83. 83. Shamanna RA, Lu H, de Freitas JK, Tian J, Croteau DL, Bohr VA. 2016. WRN regulates pathway choice between classical and alternative non-homologous end joining. Nat Commun 7:13785. 84. Saintigny Y, Makienko K, Swanson C, Emond MJ, Monnat RJ Jr. 2002. Homologous recombination resolution defect in werner syndrome. Mol Cell Biol. 22:6971-8. 85. Sturzenegger A, Burdova K, Kanagaraj R, Levikova M, Pinto C, Cejka P, Janscak P. 2014. DNA2 cooperates with the WRN and BLM RecQ helicases to mediate long-range DNA end resection in human cells. J Biol Chem. 289:27314-26. 86. Pichierri P, Ammazzalorso F, Bignami M, Franchitto A. 2011. The Werner syndrome protein: linking the replication checkpoint response to genome stability. Aging 3: 311–8. 87. Ding SL, Shen CY. 2008. Model of human aging: recent findings on Werner's and Hutchinson-Gilford progeria syndromes. Clin Interv Aging. 3:431-44. 88. Yannone SM, Roy S, Chan DW, Murphy MB, Huang S, Campisi J, Chen DJ. 2001. Werner syndrome protein is regulated and phosphorylated by DNA-dependent protein kinase. J Biol Chem. 276:38242-8. 89. Cooper MP, Machwe A, Orren DK, Brosh RM, Ramsden D, Bohr VA. 2000. Ku complex interacts with and stimulates the Werner protein. Genes Dev. 14:907-12. 90. Kusumoto-Matsuo R, Ghosh D, Karmakar P, May A, Ramsden D, Bohr VA. 2014. Serines 440 and 467 in the Werner syndrome protein are phosphorylated by DNA-PK and affects its dynamics in response to DNA double strand breaks. Aging (Albany NY). 6:70-81 91. Sakamoto S, Nishikawa K, Heo SJ, Goto M, Furuichi Y, Shimamoto A. 2001. Werner helicase relocates into nuclear foci in response to DNA damaging agents and co-localizes with RPA and Rad51. Genes Cells. 6:421-30. 92. Cheng WH, Kusumoto R, Opresko PL, Sui X, Huang S, Nicolette ML, Paull TT, Campisi J, Seidman M, Bohr VA. 2006. Collaboration of Werner syndrome protein and BRCA1 in cellular responses to DNA interstrand cross-links. Nucleic Acids Res. 34:2751-60. 93. Weller GR, Kysela B, Roy R, Tonkin LM, Scanlan E, Della M, Devine SK, Day JP, Wilkinson A, d'Adda di Fagagna F, Devine KM, Bowater RP, Jeggo PA, Jackson SP, Doherty AJ. 2002. Identification of a DNA nonhomologous end-joining complex in bacteria. Science. 297:1686-9. 94. Rathmell WK, Chu G. 1994. Involvement of the Ku autoantigen in the cellular response to DNA double-strand breaks. Proc Natl Acad Sci U S A. 91:7623-7. 95. Mimori T, Hardin JA, Steitz JA. 1986. Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from patients with rheumatic disorders. J Biol Chem. 261:2274-8. 96. Kim JS, Krasieva TB, Kurumizaka H, Chen DJ, Taylor AM, Yokomori K. 2005. Independent and sequential recruitment of NHEJ and HR factors to DNA damage sites in mammalian cells. J Cell Biol. 170:341-7. 97. Krejci L, Altmannova V, Spirek M, Zhao X. 2012. Homologous recombination and its regulation. Nucleic Acids Res. 40:5795-818. 98. Clerici M, Mantiero D, Guerini I, Lucchini G, Longhese MP. 2008. The Yku70-Yku80 complex contributes to regulate double-strand break processing and checkpoint activation during the cell cycle. EMBO Rep. 9:810-8. 99. Tomita K, Matsuura A, Caspari T, Carr AM, Akamatsu Y, Iwasaki H, Mizuno K, Ohta K, Uritani M, Ushimaru T, Yoshinaga K, Ueno M. 2003. Competition between the Rad50 complex and the Ku heterodimer reveals a role for Exo1 in processing double-strand breaks but not telomeres. Mol Cell Biol. 23:5186-97. 100. Douglas P, Gupta S, Morrice N, Meek K, Lees-Miller SP. 2005. DNA-PK-dependent phosphorylation of Ku70/80 is not required for non-homologous end joining. DNA Repair (Amst). 4:1006-18. 101. Cho HS, Ha NC, Kang LW, Chung KM, Back SH, Jang SK, Oh BH. 1998. Crystal structure of RNA helicase from genotype 1b hepatitis C virus. A feasible mechanism of unwinding duplex RNA. J Biol Chem. 273:15045-52. 102. Pan RY, Hung TM, Kou YH, Chan NL, Chang MF, Chang SC. 2010. In trans interaction of hepatitis C virus helicase domains mediates protease activity critical for internal NS3 cleavage and cell transformation. FEBS Lett. 584:482-6. 103. Kou YH, Chou SM, Wang YM, Chang YT, Huang SY, Jung MY, Huang YH, Chen MR, Chang MF, Chang SC. 2006. Hepatitis C virus NS4A inhibits cap-dependent and the viral IRES-mediated translation through interacting with eukaryotic elongation factor 1A. J Biomed Sci. 13:861-74. 104. Pierce AJ, Johnson RD, Thompson LH, Jasin M. 1999. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 13:2633-38. 105. Ko YC, Tsai WH, Wang PW, Wu IL, Lin SY, Chen YL, Chen JY, Lin SF. 2012. Suppressive regulation of KSHV RTA with O-GlcNAcylation. J Biomed Sci 19:12. 106. Chen L, Huang S, Lee L, Davalos A, Schiest RH, Campisi J, Oshima J. 2003. WRN, the protein deficient in Werner syndrome, plays a critical structural role in optimizing DNA repair. Aging Cell 2:191-9. 107. Lai JS, and Herr W. 1992. Ethidium bromide provides a simple tool for identifying genuine DNA-independent protein associations. Proc Natl Acad Sci U S A 89:6958–62. 108. Bau DT, Mau YC, Ding SL, Wu PE, Shen CY. 2007. DNA double-strand break repair capacity and risk of breast cancer. Carcinogenesis 28:1726-30. 109. Alexandre S, Nakaki T, Vanhamme L, Lee AS. 1991. A binding site for the cyclic adenosine 3',5'-monophosphate-response element-binding protein as a regulatory element in the grp78 promoter. Mol Endocrinol. 5:1862-72. 110. Jackson SP, Boulton SJ. 1996. Saccharomyces cerevisiae Ku70 potentiates illegitimate DNA double-strand break repair and serves as a barrier to error-prone DNA repair pathways. EMBO J 15:5093-103. 111. Liang L, Deng L, Chen Y, Li GC, Shao C, Tischfield JA. 2005. Modulation of DNA end joining by nuclear proteins. J Biol Chem 280:31442-9. 112. Mimitou EP, Symington LS. 2009. Nucleases and helicases take center stage in homologous recombination. Trends Biochem Sci 34:264-72. 113. Chang HHY, Pannunzio NR, Adachi N, Lieber MR. 2017. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol 18:495-506. 114. Jung D, Alt FW. 2004. Unraveling V(D)J recombination insight into gene regelation. Cell 116:299–311. 115. Shrivastav M, De Haro LP, Nickoloff JA. 2008. Regulation of DNA double-strand break repair pathway choice. Cell Res 18:134-47. 116. Lorenzini A, Johnson FB, Oliver A, Tresini M, Smith JS, Hdeib M, Sell C, Cristofalo VJ, Stamato TD. 2009. Significant correlation of species longevity with DNA double strand break recognition but not with telomere length. Mech Ageing Dev 130:784-92. 117. Yuan Kai Hsu. 2018. Interactions between hepatitis C virus NS3 protein and DNA double-strand break repair factors. Graduate Institute of Microbiology, College of Medicine, National Taiwan University. 118. Li B, Comai L. 2000. Functional interaction between Ku and the werner syndrome protein in DNA end processing. J Biol Chem. 275:28349-52. 119. Nguyen TTT, Park EM, Lim YS, Hwang SB. 2018. Nonstructural protein 5A impairs DNA damage repair: implications for hepatitis C virus-mediated hepatocarcinogenesis. J Virol 92:e00178-18 120. Mahaney BL, Meek K, Lees-Miller SP. 2009. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J 417:639-50. 121. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. 1993. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol. 67:1385-95. 122. Pham HT, Nguyen TTT, Nguyen LP, Han SS, Lim YS, Hwang SB. 2019. Hepatitis C virus downregulates ubiquitin-conjugating enzyme E2S expression to prevent proteasomal degradation of NS5A, leading to host cells more sensitive to DNA damage. J Virol 93:e01240-18. 123. Hasty P, Campisi J, Hoeijmakers J, van Steeg H, Vijg J. 2003. Aging and genome maintenance : lessons from the mouse? Science 299:1355-59. 124. Navarro CL, Cau P, Levy N. 2006. Molecular bases of progeroid syndromes. Hum Mol Genet 15:R151 -61. 125. Hollingworth R, Grand RJ. 2015. Modulation of DNA damage and repair pathways by human tumour viruses. Viruses. 7:2542-91. 126. Baydoun HH, Pancewicz J, Nicot C. 2011. Human T-lymphotropic type 1 virus p30 inhibits homologous recombination and favors unfaithful DNA repair. Blood. 117:5897-906. 127. Xiao Y, Chen J, Liao Q, Wu Y, Peng C, Chen X. 2013. Lytic infection of Kaposi's sarcoma-associated herpesvirus induces DNA double-strand breaks and impairs non-homologous end joining. J Gen Virol. 94:1870-5. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/74847 | - |
dc.description.abstract | C型肝炎病毒與肝細胞癌的形成相關,病毒NS3蛋白質具有絲胺酸蛋白酶及解旋酶雙重活性。過去的研究顯示NS3蛋白質會抑制DNA修復並與細胞轉型作用有關;然而,NS3蛋白質參與在細胞癌化的機制仍未完全瞭解。在哺乳動物細胞中,DNA的修復是經由許多複雜的機制相互調控構成的系統,在這些複雜的調控當中,WRN在許多修復機制上均扮演了重要的角色,包含非同源性末端接合修復 (NHEJ repair)。在以往的研究中已知Ku蛋白質參與在啟動NHEJ修復的機制中,且與WRN具交互作用,有助於相互的調控。在本研究中發現,NS3蛋白質會與WRN及Ku70蛋白質有交互作用,並且在C型肝炎病毒次基因體複製系統及表現NS3蛋白質的Huh7細胞當中,WRN所調控之修復機制有拖延的現象,NHEJ修復效率也呈現下降的趨勢。NS3蛋白質亦會改變細胞核內WRN與Ku70蛋白質的分布,並干擾Ku70結合到DNA雙股斷裂處,這樣的發現可用於解釋為何NS3蛋白質會抑制NHEJ修復。同時,本研究也發現WRN蛋白質不但會受到蛋白酶體降解,其存在量也與NS3-4A蛋白酶的活性有關。C型肝炎病毒NS3蛋白質對WRN參與的NHEJ修復作用及WRN蛋白質降解的雙重影響,可能導致DNA突變的累積、增加基因的不穩定性、甚至腫瘤的生成。 | zh_TW |
dc.description.abstract | Hepatitis C virus (HCV) is associated with the development of hepatocellular carcinoma. The viral NS3 protein, acting as serine protease and helicase, was shown to inhibit DNA repair and involve in cell transformation. However, implications of the HCV NS3 in the mechanisms of oncogenesis are not fully understood. DNA repair pathways in mammalian cells are mediated by complicated mechanisms. Among these, Werner syndrome protein (WRN) plays a major role in multiple repair pathways, including non-homologous end joining (NHEJ) repair. Ku protein was previously demonstrated to interact with WRN and involve in the initiation of NHEJ repair. In this study, HCV NS3 protein was found to interact with WRN and Ku70. In addition, WRN-mediated DNA repair was prolonged and the efficiency of overall NHEJ repair was reduced in both an HCV subgenomic replicon system and Huh7 cells expressing NS3. NS3 alters the nuclear distribution of WRN and Ku70. It interferes with the recruitment of Ku70 to the DNA DSB sites. This may partially explain why NS3 inhibits NHEJ repair. In addition, the level of WRN is regulated by both the proteasome degradation and the activity of NS3-4A protease. The dual role of HCV NS3 in regulating the function and expression level of the WRN protein provides possible mechanisms of HCV in the impairment of DNA repair. The impairment may lead to an accumulation of DNA mutation and genome instability and, eventually, tumor development. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T09:08:45Z (GMT). No. of bitstreams: 1 ntu-108-D98445001-1.pdf: 6267172 bytes, checksum: 5fb0b92f0da721bc4ea7fd3c1c0e441f (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 中文摘要…..…....……………………………………………………………………i
Abstract………………………………………..……………………………………ii Contents………………………………………………………………………….iv Chapter 1: Introduction……………………………………………………..….. 1 1.1. General introduction for HCV………………………………………………1 1.1.1. History…….………………………………………………………………1 1.1.2. Virology……………………………………………………………………1 1.1.3. Epidemiology………………………………………………………………2 1.1.4. The genome and structure of HCV………………………………………3 1.1.4.1. Structural proteins………………………….…………………………3 1.1.4.2. Non-structural proteins……………….………………………………5 1.1.5. HCV prevention and treatment…….………………………………………8 1.2. Roles of HCV NS3 in HCC development……………………………………9 1.3. DNA damage responses and repair pathways…………...…………………….11 1.3.1. NHEJ repair……………………………………………………………11 1.3.2. Microhomology mediated end joining (MMEJ) repair…………………12 1.3.3. Homologous recombination……………………………………………...13 1.4. The roles of Werner syndrome protein (WRN) and Ku70 in DNA repair…13 1.4.1. WRN……………………………......…………………………………….13 1.4.2. Ku70……………………………………..………………………………15 Chapter 2: Specific aims…………………………………………….……………17 2.1. To study the effects of HCV NS3 on DNA repair……………………………...17 2.2. To assess whether WRN can be a substrate of NS3-4A protease……………...17 Chapter 3: Materials and Methods…………………………………………………19 3.1. Materials……………………………………………………………………...19 3.1.1. Chemicals and reagents………………………..…………………………19 3.1.2. Enzymes…….……………………………………………………………21 3.1.3. Antibodies.…..……….…………………………………………………21 3.1.4. Kits…………………….…………………………………………………21 3.1.5. Buffers…………………………………………………………………23 3.2. Plasmids……………………………………………………………………24 3.2.1. Vector control plasmids…………………………..………………………24 3.2.2. Expression plasmids……………………………..………………………24 3.3. Cell lines……………………………………………………………………28 3.3.1. 293T cell line…………………………………………………………......28 3.3.2. Huh7 cell line………………………………………………………….....28 3.3.3. TR-NS3, TR-NS3-4A, and TR-NS3pd-4A cell lines………………….....28 3.3.4. HCVR cell line…………………………………………………………29 3.4. Production of lentiviral particles…………………………………………....29 3.5. Expression of GST fusion protein and GST-pull down assay…………….....29 3.6. Immunoprecipitation and Western blot analysis…………………………….30 3.7. Cellular fractionation……………………………………………............….31 3.8. Immunofluorescence staining………………………………………………31 3.9. Knockdown of WRN…………………………………………………………33 3.10. NHEJ assay………………………………………………...………….…….34 3.11. HR assay…………………………………………………….................……35 3.12. DNA pull down assay……………………………........…………………36 3.13. WRN cleavage assay……………………………………….................……..36 Chapter 4 Results………………………………………………….....………………37 4.1 HCV NS3 protein interacts with WRN, a member of the RecQ family………..37 4.2 HCV NS3 impairs WRN/Ku-mediated NHEJ repair…………………………..38 4.2.1 HCV NS3 and NS3-4A protein impair WRN-mediated DNA repair……...38 4.2.2 NS3 protein interacts with Ku70 and impairs NHEJ repair……………….40 4.2.3 HCV NS3 protein interferes with WRN and Ku70 recruitment to the DSB sites………………………………………………………..…….…….42 4.3 WRN is a substrate of NS3-4A protease………….……………………….....44 4.3.1 WRN level is down-regulated in HCVR cells comparing to the Huh7 control cells……………………………………………………………..........44 4.3.2 WRN level is regulated by both the proteasome and NS3-4A protease activity………………………….………………………………….....44 4.3.3 WRN is a substrate of NS3-4A protease……………………………......45 Chapter 5 Discussion………………………………………………………………...48 Chapter 6 Figures………………………………………………………………….....52 Fig. 1. HCV NS3 protein interacts with WRN……………………………….....52 Fig. 2. Fractionation of the HCV NS3 protein and WRN……………………….....54 Fig. 3. HCV nonstructural proteins inhibit WRN activation and impair DNA repair at an initial step……………………………………………………….....55 Fig. 4.HCV protein-induced impairment of DNA repair is associated with WRN………………………………………………….…………………56 Fig. 5. NS3 protein interacts with Ku70……………………....…………………...58 Fig. 6. HCV NS3 and NS3-4A inhibit NHEJ repair……………………………......59 Fig. 7. HCV nonstructural proteins alter the nuclear distribution of repair complex in CPT-treated cells……………………………………………………......61 Fig. 8. HCV protein interferes with the formation of repair complex……………63 Fig. 9. DNA pull-down assay……………………………………………………...65 Fig. 10. WRN level is reduced in HCVR cells…………………………………...67 Fig. 11. The level of WRN protein is regulated by the proteasome and HCV NS3 protease activity………..…......………………………………………….68 Fig. 12. HCV NS3-4A reduces the stability of WRN……………………………...69 Fig. 13. WRN is a substrate of HCV NS3-4A protease………………………….....70 Fig. 14. NHEJ assay in TR-NS3-4A and TR-NS3pd-4A………………………...72 Fig. 15. Examination of NS3-4A protease cleavage site on WRN…........................73 Chapter 7 References…………………………………………………………….74 Chapter 8 Appendix ……………………………………………………………….87 | |
dc.language.iso | en | |
dc.title | C型肝炎病毒非結構性蛋白質NS3在WRN參與調控之非同源性末端接合修復上具雙重作用 | zh_TW |
dc.title | Hepatitis C Virus NS3 Protein Plays a Dual Role in WRN-Mediated Repair of Non-Homologous End Joining | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 蔡錦華(Ching-Hwa tsai),鄧述諄(Shu-Chun Teng),王萬波(Won-Bo Wang),方偉宏(Woei-Horng Fang),林素芳(Su-Fang Lin) | |
dc.subject.keyword | C型肝炎病毒,NS3蛋白質,非同源性末端接合修復,WRN,Ku70, | zh_TW |
dc.subject.keyword | hepatitis C virus (HCV),nonstructural protein 3 (NS3),non-homologous end joining (NHEJ) repair,WRN,Ku70, | en |
dc.relation.page | 105 | |
dc.identifier.doi | 10.6342/NTU201904252 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-10-31 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 6.12 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。